Physician profile
Marc Moon
NPI 1528086162
$141,617.75
in general payments reported to CMS, 2019-2025
11 companies · $37K in 2025
The $37K reported for 2025 was more than what 96% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $13K · 2021: $3,978 · 2022: $22K · 2023: $24K · 2024: $16K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Travel and Lodging: $33K · Food and Beverage: $5,102 · Grant: $1,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,343.75 |
| Travel and Lodging | $32,674.00 |
| Food and Beverage | $5,101.59 |
| Grant | $1,494.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $84,194.39 | 2019-2025 | Mitris Resilia Mitral Valve, Inspiris Resilia Aortic Valve |
| Medtronic Vascular, INC. | $34,022.61 | 2019-2020 | |
| Medtronic, INC. | $15,102.83 | 2021-2025 | Avalus, Corevalve Evolut R |
| Atricure, INC. | $5,000.00 | 2023 | |
| Artivion, INC. | $2,633.66 | 2021-2022 | |
| Abiomed | $414.43 | 2022-2023 | Impella |
| Abbott Laboratories | $128.18 | 2021 | |
| Baxter Healthcare | $70.71 | 2019 | |
| Ethicon US, LLC | $32.68 | 2023 | Prolene |
| Janssen Pharmaceuticals, INC | $18.26 | 2023 | Xarelto |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.